Arrayit Corporation and Parkinson’s Institute Implement New Screening Techniques for Identification of Molecular Biomarkers – New Technology to Help Researchers Better Understand the Origin of Parkinson’s

Arrayit Corporation (OTC.BB:ARYC – News), a proprietary life sciences technology leader, announces a research collaboration with The Parkinson’s Institute of Sunnyvale, California to discover biomarkers for Parkinson’s disease. This unique study involves the prospective collection of samples from well-characterized Parkinson’s patients utilizing two proprietary platforms; Arrayit’s new H25K microarray and PlasmaScan(TM) 80. The first studies have enabled rapid and efficient sample preparation of specimens from Parkinson’s disease patients, an important step in the discovery of molecular markers for Parkinson’s disease.

“This collaboration provides an important first step towards unraveling the mysteries of Parkinson’s disease,” stated Dr. Mark Schena, Ph.D., Arrayit President. “We are working diligently with The Parkinson’s Institute to decipher the molecular basis of the disease,” he continued. The Parkinson’s Institute Assistant Professor Dr. Birgitt Schuele, M.D. added, “Parkinson’s disease represents a serious and challenging medical condition and we are pleased to be deploying Arrayit technology to combat this illness.”

About Arrayit’s H25K Microarray and PlasmaScan(TM) 80 Technologies

Since the human Genome was finally mapped in 2003, disclosing the 25,000 genes that comprise the human DNA, Arrayit has developed the H25K microarray platform that contains and prints the entire human genome. H25K allows researchers and clinicians to examine the patient’s entire genome and test blood samples against a known disease state. This allows clinicians to determine which gene is manifesting that particular disease.

In order to be more finite in determining Parkinson’s markers, Arrayit has created the market’s only antibody microarray containing monoclonal antibodies generated against native human plasma proteins. The PlasmaScan(TM) antibodies are provided by BioSystems International. They react with native human proteins with proper folding and post-translation modification to exhibit high antibody binding. The Arrayit microarray platform with the PlasmaScan(TM) monoclonal antibodies enables the exploration and identification of novel biomarkers in the human plasma proteome.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company’s business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.